Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery
Year: 2020
Type: article
Abstract: Despite the worldwide reemergence of the chikungunya virus (CHIKV) and the high morbidity associated with CHIKV infections, there is no approved vaccine or antiviral treatment available. Here, we aimed to identify the target of a novel class of CHIKV inhibitors, i.e., the CHVB series. CHVB compounds inhibit the in vitro replication of CHIKV isolates with 50% effective concentrations in the low-micromolar range. A CHVB-resistant variant (CHVB res ) was selected that carried two mutations in the gene encoding nsP1 (responsible for viral RNA capping), one mutation in nsP2, and one mutation in nsP3.
DOI: 10.1128/aac.00649-20
Institutions: Rega Institute for Medical Research, KU Leuven, Leiden University Medical Center, Universität Innsbruck, University of Vienna, Inserm, Aix-Marseille Université, Méditerranée Infection Foundation, Institut de Recherche pour le Développement, Unité des Virus Emergents, Centre National de la Recherche Scientifique, Architecture et Fonction des Macromolécules Biologiques
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: European Commission, KU Leuven
OpenAlex ID: W3018421507